Témoignage Intégral de Carine Curtet
Présidente de l'Association AMETIST
Témoignage Intégral du Dr Delépine
Pour le film Cancer Business Mortel
Si vous souhaitez contacter Nicole Delepine
Rendez-vous sur son site :
|
|
 |
 |
CONFLICTS OF INTERESTS FOR MARKETING AUTHORIZATION OF A MEDICINE
NECESSITY OF A NEW JURISDICTION
G. Delepine et N. Delépine HOPITAL UNIVERSITAIRE RAYMOND POINCARE à garches
GEIRSO 2009 Milan 21 au 24 septembre 2009
The scandal of the VIOXX
1999-2004 Vioxx gave 2,5 bllions $ benefit every year
Doctor D.Graham 17/11/2005 Â"a realistic and likely range of estimates for the number of victims in the US was between 88,000 and 139,000. Of these, 30-40 percent probably died. Â"
The current MA procedures are above all characterized by the opaqueness
like inquisition procedures :
only the decisions are public
MA data and motivations remain secret..
Trials data are the exclusive property of the laboratory
which can decide the scheme of the trial,
The end point,
The type of analysis
To publish or not, or partially
Can alter data, include ghost patients or exclude some patients with complications
without any independent control
All trials should be published
Many results are never published, especially when clinical trials show that a drug or treatment didn't work or have unexpected toxicity. So the medical community remains in the dark over what was learned.
Â" less than 1 in 5 Cancer Trials Are Published.. Â"Â"In trials sponsored by industry, the rate was even lower: Just 1 in 20 is published.. Â"
The investigators
The investigators are motivated by high fees which often distort their conclusions
8th april 2008, Kassirer in le Los Angeles Times published Tainted Medicine showing the importance of conflicts in Financial interest
Â"can we trust in medical research? Â"
And for whistle blowers investigators
En avril 1993, le docteur Nancy Olivieri, de l’Hôpital des enfants malades de Toronto, signe avec la société Apotex Research Inc. un protocole de recherche sur une nouvelle molécule, la défériprone,. Deux ans après le début des essais thérapeutiques et la publication de premiers résultats encourageants, elle suspecte ce médicament d’aggraver la fibrose hépatique de certains de ses malades.
Experts of the committees of MA
No experts of the committees of MA are independent from firms.
This situation is the result
of the faith that medical research "would be motivated only by interest of the patients or science" .
"today profits are tomorrow medicines" assertions denied by objective analysis : the profits of firms especially served for increasing dividends while credits allocated to research and number of real new medicines decreased
MA is a judgment on the harmlessness and the efficiency of the product.
But if democratic justice bases on
the contradictory and
public examination of all the elements of proof
Propositions for transparency.
The clinical trials intended to support a file of MA have to recover from a particular legal regime to have convincing value
A new regime of property
Their regime of property will be the one of a shared co-ownership enter
the laboratory which finances,
the patients who take the risk and
the State or the welfare organization which will pay the future medicine
Authentic data
The medical data of the trials have to be authentified
With a registration of main data at the health Autority every year (as we do for commercial firms)
and to be published with independent rewievers even in case of interruption of the trial.
Recommandations de Transparency International
Base de données publiques sur les essais cliniques des médicaments
Publications des éventuels conflits d’intérêts
Code de conduite : Un Code de Déontologie pour les professionnels de santé, les administrations de santé, les organes de contrôle, intégrant des sanctions.
Code de conduite pour les industries pharmaceutiques et de DM pour ne pas verser des pots-de-vin.
Implication et rôle de surveillance de la société civile
Protection des dénonciateurs
|  Consulter le document dans sa version complete |
|
 |
|
L'ASSOCIATION
